Isis Innovation Limited;GVMT of the USA, as represented by The Secretary, Department of Health & Human Services
发明人:
Veech, Richard Lewis,Clarke, Kieran
申请号：
AU2009204370
公开号：
AU2009204370B2
申请日:
2009.01.05
申请国别(地区):
AU
年份:
2014
代理人:
摘要：
The subject disclosure provides compositions for reducing serum cholesteroland/or triglyceride levels in subjects. These compositions can comprise racemicβ-hydroxybutyrate or D-β-hydroxybutyrate, optionally in theacid form, physiologically compatible salts of racemic β-hydroxybutyrateor D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomersof D-β-hydroxybutyrate containing from 2 to 20 or more monomeric unitsin either linear or cyclic form, racemic 1,3 butandiol or R- 1,3 butandiol aloneand can be, optionally, administered in conjunction with a low fat diet to a subject.Alternatively, compositions comprising racemic β-hydroxybutyrateor D-β-hydroxybutyrate, optionally in the acid form, physiologicallycompatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate,esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyratecontaining from 2 to 20 or more monomeric units in either linear or cyclic form,racemic 1,3 butandiol, R- 1,3 butandiol or combinations thereof can be formulatedas nutritional supplements (also referred to as nutritional compositions)or incorporated into therapeutic compositions containing a) anti- hypertensiveagents； b) anti-inflammatory agents； c) glucose lowering agents； or d) anti-lipemic agents) which are administered to a subject, optionally in combinationwith a low fat diet, in order to cause a reduction or lowering of: serum cholesterollevels； triglyceride levels； serum glucose levels, serum homocysteine levels,inflammatory proteins (e.g., C reactive protein) and/or hypertension in treatedsubjects. Alternatively, compositions disclosed herein can be administeredalone, or in combination with other therapeutic agents to prevent or reversevascular disease.
